Open AccessEffects of Olmesartan‐Based Treatment on Masked, White‐Coat, Poorly Controlled, and Well‐Controlled Hypertension: HONEST Study
Author(s) -
Kario Kazuomi,
Saito Ikuo,
Kushiro Toshio,
Teramukai Satoshi,
Ishikawa Yusuke,
Kobayashi Fumiaki,
Shimada Kazuyuki
Publication year - 2014
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.12323
Subject(s) - olmesartan , medicine , morning , blood pressure , masked hypertension , white coat hypertension , ambulatory blood pressure , cutoff , isolated systolic hypertension , cardiology , evening , physics , quantum mechanics , astronomy
The authors examined the effects of olmesartan‐based treatment on clinic systolic blood pressure ( CSBP ) and morning home systolic blood pressure ( HSBP ) in 21,340 patients with masked hypertension ( MH ), white‐coat hypertension ( WCH ), poorly controlled hypertension ( PCH ), and well‐controlled hypertension ( CH ) using data from the Home Blood Pressure Measurement With Olmesartan Naive Patients to Establish Standard Target Blood Pressure ( HONEST ) study. MH , WCH , PCH , and CH were defined using CSBP 140 mm Hg and MHSBP 135 mm Hg as cutoff values at baseline. At 16 weeks, the MH , WCH , PCH , and CH groups had changes in CSBP by −1.0, −15.2, −23.1, and 1.8 mm Hg, and changes in morning HSBP by −12.5, 1.0, −20.3, and 2.0 mm Hg, respectively. In conclusion, in “real‐world” clinical practice, olmesartan‐based treatment decreased high morning HBP or CBP without excessive decreases in normal morning HBP or CBP according to patients' BP status.